menu
    • menu
    [{"orgOrder":0,"company":"Jina Pharmaceuticals","sponsor":"Novum Pharmaceutical Research Services | Lambda Therapeutic Research Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Jina Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services | Lambda Therapeutic Research Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services | Lambda Therapeutic Research Ltd"},{"orgOrder":0,"company":"Jina Pharmaceuticals","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Jina Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Jina Pharmaceuticals","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Jina Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"8","companyTruncated":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Jina Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Jina Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jina Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jina Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jina Pharmaceuticals","sponsor":"Intas Pharmaceuticals | Lambda Therapeutic Research Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Jina Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Jina Pharmaceuticals \/ Intas Pharmaceuticals | Lambda Therapeutic Research Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Jina Pharmaceuticals \/ Intas Pharmaceuticals | Lambda Therapeutic Research Ltd"},{"orgOrder":0,"company":"Jina Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Jina Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Jina Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jina Pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Jina Pharmaceuticals

    Menu

    Jina Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jina Pharmaceuticals

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Jina Pharmaceuticals

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cabazitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Parti...

                            Details : Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 24, 2025

                            Lead Product(s) : Cabazitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jina Pharmaceuticals

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Jina Pharmaceuticals

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Novum Pharmaceutical Research Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcer...

                            Details : Tacrolimus is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            March 10, 2025

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Novum Pharmaceutical Research Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Jina Pharmaceuticals

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Jina Pharmaceuticals

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer

                            Details : Paclitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Peritoneal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 10, 2025

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Jina Pharmaceuticals

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Jina Pharmaceuticals

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Novum Pharmaceutical Research Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

                            Details : Endoxifen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bipolar Disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 23, 2024

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Novum Pharmaceutical Research Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Jina Pharmaceuticals

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Jina Pharmaceuticals

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Novum Pharmaceutical Research Services | Lambda Therapeutic Research Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

                            Details : Endoxifen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bipolar Disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 20, 2020

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Novum Pharmaceutical Research Services | Lambda Therapeutic Research Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Jina Pharmaceuticals

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Jina Pharmaceuticals

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Docetaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Intas Pharmaceuticals | Lambda Therapeutic Research Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast ...

                            Details : Docetaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Triple Negative Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 14, 2018

                            Lead Product(s) : Docetaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Intas Pharmaceuticals | Lambda Therapeutic Research Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth